Previous 10 | Next 10 |
2023-05-03 14:00:40 ET Image source: The Motley Fool. BioCryst Pharmaceuticals (NASDAQ: BCRX) Q1 2023 Earnings Call May 03, 2023 , 8:30 a.m. ET Operator Continue reading For further details see: BioCryst Pharmaceuticals (BCRX) Q1 2023 Ear...
2023-05-03 12:04:04 ET BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2023 Earnings Conference Call May 03, 2023 08:30 AM ET Company Participants John Bluth - Investor Relations Jon Stonehouse - Chief Executive Officer Anthony Doyle - Chief Financial Officer Charli...
2023-05-03 07:05:57 ET BioCryst Pharmaceuticals press release ( NASDAQ: BCRX ): Q1 GAAP EPS of -$0.28 beats by $0.03 . Revenue of $68.78M (+37.8% Y/Y) misses by $2.66M . The increase was primarily due to $68.4 million in ORLADEYO net revenue in the first quarte...
—Q1 2023 ORLADEYO net revenue grows 38 percent y-o-y to $68.4 million— —Strong ORLADEYO new patient growth in Q1: 46 percent increase in patients on therapy y-o-y, including eight percent growth q-o-q— —Over 1,000 U.S. patients on ORLAD...
RESEARCH TRIANGLE PARK, N.C., April 27, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced new data from the APeX-S clinical trial, which evaluated oral, once-daily ORLADEYO ® (berotralstat) for the prophylactic treatment of hereditary angioed...
RESEARCH TRIANGLE PARK, N.C., April 19, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its first quarter 2023 financial results on Wednesday, May 3, 2023. BioCryst management will host a conference call and webcast ...
2023-04-18 09:56:29 ET BioCryst Pharmaceuticals ( NASDAQ: BCRX ) has refinanced its existing debt with $450M financing commitment from funds managed by Pharmakon Advisors. The new five-year credit facility bears interest at the 3-month SOFR + 7.00% (subject to a 1.75% floo...
RESEARCH TRIANGLE PARK, N.C., April 18, 2023 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company has secured $450 million in committed financing from funds managed by Pharmakon Advisors, LP. BioCryst has elected to draw $300 million of the $450 m...
2023-04-12 06:00:00 ET Summary If a stock has a high short interest, it means that there are many investors who have bet against the stock and shorted it. The collapse of Silicon Valley Bank and the ensuing domino effect has resulted in short sellers wanting to capitalize on wides...
2023-04-04 22:01:45 ET Summary Baker Brothers’ 13F portfolio value increased from $15.27B to $16.65B this quarter. Replimune Group stake was substantially increased this quarter. The top three positions are Seagen, Incyte Corporation, and BeiGene, and they add up to alm...
News, Short Squeeze, Breakout and More Instantly...
BioCryst Pharmaceuticals Inc. Company Name:
BCRX Stock Symbol:
NASDAQ Market:
BioCryst Pharmaceuticals Inc. Website:
RESEARCH TRIANGLE PARK, N.C., July 09, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the General Directorate of Medicines, Supplies and Drugs (DIGEMID) in Peru has granted approval for oral, once-daily ORLADEYO ® (berotralstat) for t...
2024-06-27 04:12:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-06-07 10:20:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...